Abstract: Objective To investigate the efficacy and mechanism of Dengzhan Shengmai capsule combined with lovastatin in elderly patients with coronary heart disease. Methods 80 elderly patients with coronary heart disease admitted to Tianshui First People's Hospital from March 2020 to December 2021 were selected and divided into two groups according to the random number table method. The control group was treated with lovastatin, and the observation group was treated with Dengzhan Shengmai Capsules and lovastatin. The effective rate of treatment in the two groups was observed, the cardiac function indexes, homocysteine (Hcy), high-sensitivity C-reactive protein (hs-CRP) and uric acid (UA) levels in the two groups were detected, and the hemorheological indexes of the two groups were detected. Results The effective rate of the observation group was significantly higher than control group (P<0.05). Before treatment, there was no statistical significant difference in LVESV, LVEDD, LVEF and LVESD between the two groups (P>0.05). After treatment, LVESV, LVEDD, LVEF and LVESD in the two groups were significantly improved (P<0.05). The index was significantly better than the control group (P<0.05). Before treatment, there was no statistical significant difference in the levels of UA, hs-CRP and Hcy between the two groups (P>0.05). After treatment, the levels of UA, hs-CRP and Hcy in the two groups were significantly decreased (P<0.05). The levels of UA, hs-CRP and Hcy were significantly lower than those in the control group (P<0.05). Before treatment, there was no statistical significant difference in the erythrocyte aggregation index, plasma viscosity, maximum platelet aggregation rate and fibrinogen between the two groups (P>0.05). After treatment, the erythrocyte aggregation index, plasma viscosity, maximum platelet aggregation rate and fibrinogen between the two groups The erythrocyte aggregation index, plasma viscosity, maximum platelet aggregation rate and fibrinogen in the observation group were significantly lower than those in the control group (P<0.05). Conclusion Dengzhan Shengmai capsule combined with lovastatin has better curative effect on elderly patients with coronary heart disease, and the mechanism may be related to reducing the levels of UA, hs-CRP and Hcy, and regulating the levels of inflammatory factors.

Key words: Dengzhan Shengmai Capsule, lovastatin, coronary heart disease in the elderly, efficacy, mechanism of action